adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion (VECTOR)
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four ... passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi (25-28). This could, be related to worst clinical outcome at 3 months. VECTOR asks a relevant question: Do the invetigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots?
연구 개요
상태
정황
상세 설명
Sudden occlusion of an intracranial artery by a thrombus represents the initial and pivotal event of large vessel occlusion acute ischemic stroke (AIS). The primary goal of AIS treatment is to re-open this artery with intravenous tissue-type plasminogen activator infusion (IV t-PA) and/or endovascular therapy (EVT). Thrombus characterization could be useful to predict AIS etiology, IV t-PA response and to adapt the device or technique for EVT. Especially, approaching the red blood cell (RBC) content of the thrombus would be helpful to plan a treatment strategy or identify specific EVT approaches in order to maximize the rate of early successful reperfusion .
The susceptibility vessel sign (SVS) on T2*-MRI sequence is defined as a hypo-intense signal exceeding the diameter of the contralateral artery located at the site of the thrombus. Several studies have demonstrated SVS to be a negative predictor of early reperfusion after IV t-PA and an incentive to EVT . Two studies identified a correlation between the SVS and the thrombus composition (specifically the RBC composition). In the ASTER trial, the presence of SVS impacted the success rate of the EVT strategy. In the SVS (+) sub-population of this study, compared to contact aspiration (CA), patients treated with stent retrievers achieved higher rates of complete reperfusion within fewer passes, which translated into a better functional outcome. In the absence of SVS, no differences were observed between the two techniques. Furthermore; based on the ASTER and THRACE trial populations treated with stent retriever as a first line strategy, a higher rate of favorable clinical outcome at 3 months in SVS (+) patients was recently found . Hence, that differences in terms of reperfusion results are thought to be related to different clot compositions between SVS + and SVS - occlusions.
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi. This could, be related to worst clinical outcome at 3 months.
VECTOR asks a relevant question: Do the investigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots? The hypothesis in the VECTOR trial is that the Embotrap II or III, thanks to its dedicated design will help to the stabilization of friable clots and allow better retrieving of SVS + thrombi in a lower number of passes.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
-
Amiens, 프랑스
- CHU Amiens-Picardie
-
Angers, 프랑스
- CH Angers
-
Bayonne, 프랑스, 64109
- CH Côte Basque
-
Bordeaux, 프랑스
- Hôpital Pellegrin - CHU Bordeaux
-
Brest, 프랑스
- CHRU Brest
-
Le Kremlin-Bicêtre, 프랑스
- Hôpital Bicêtre
-
Lille, 프랑스
- Hôpital Roger Salengro - CHR Lille
-
Limoges, 프랑스
- CHU Limoges
-
Lyon, 프랑스
- Hospices Civils Lyon
-
Marseille, 프랑스, 13385
- CHU Marseille - Hôpital la Timone
-
Montpellier, 프랑스
- CHU Gui de Chauliac
-
Nancy, 프랑스
- CHU Nancy
-
Nantes, 프랑스
- CHU de Nantes
-
Paris, 프랑스, 75019
- Fondation Ophtalmologique Adolphe de Rothschild
-
Paris, 프랑스
- La Pitié Salpétrière
-
Paris, 프랑스
- Hôpital Ste Anne
-
Pau, 프랑스, 64000
- CH Pau
-
Reims, 프랑스
- Hôpital Maison Blanche - CHU Reims
-
Rennes, 프랑스
- Hôpital Pontchaillou - CHU Rennes
-
Strasbourg, 프랑스, 67000
- CHU Strasbourg
-
Suresnes, 프랑스
- Hôpital Foch
-
Tours, 프랑스
- Hôpital Bretonneau - CHU Tours
-
Vannes, 프랑스
- CH Bretagne Atlantique
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age 18 and older (i.e., candidates must have had their 18th birthday)
- Puncture carried out within 24 hours of first symptoms
- Suitable 1.5T MRI T2 * Gradient echo that shows a clear susceptibility vessel sign facing the occlusion
- Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation, M1 or proximal M2)
- Patient or trustworthy person informed about the study and having orally consented to participation in the study. If the patient is unable to receive information and no trustworthy person can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the investigator, in compliance with the French laws
- With or without intravenous thrombolysis
Exclusion Criteria:
- Absence of large vessel occlusion on non-invasive imaging
- Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory
- Suspected pregnancy; if, in a woman is of child-bearing potential, a urine or serum beta HCG test is positive
- Severe contrast medium allergy or absolute contraindication to use of iodinated products
- Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic
- Patient has severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient
- Acute ischemic stroke involving posterior circulation (vertebro-basilar occlusion)
- Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment
- Pregnant or breast-feeding women
- Patient benefiting from a legal protection
- Non-membership of a national insurance scheme
- Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person
- Patient with modified Rankin score > 3 before qualifying stroke
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: combined EMBOTRAP II or III and Contact Aspiration
|
refer to title
|
|
활성 비교기: Contact Aspiration alone
|
refer to title
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The rate of near to complete reperfusion after 3 passes of the device defined by a modified treatment in cerebral infarction (eTICI) score of 2c/3
기간: At Day 0 immediately after 3 passes
|
Preliminary data suggested in case of SVS+ occlusions a superiority of the first line SR strategy in terms of eTICI2c/3 after 3 passes compared to first line CA alone.The first pass (FPE) is an ambitious technical endpoint defined as a successful reperfusion obtained after the first pass that has been recently associated with an increased probability of favorable clinical outcome, a reduced mortality rate and procedural adverse events.However, this constitutes a "very technical" endpoint and the external validity in daily practice would be reduced compared to the three passes cut-off.Even if a FPE eTICI 2b, 2c or 3 has shown better clinical outcome compared to a final eTICI 2b, 2c or 3,there is no study that has proved the better clinical outcome when compared FPE eTICI 2b,2c or 3 to three passes eTICI 2b,2c or 3.Last, there was no preliminary data that suggests in case of SVS+ occlusions, a superiority of the first pass SR strategy in terms eTICI2c/3 compared to first pass CA alone.
|
At Day 0 immediately after 3 passes
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Near to complete first-pass effect
기간: Day 0 immediately after first pass
|
Defined as a eTICI 2c/3 after first pass device
|
Day 0 immediately after first pass
|
|
Complete first-pass effect
기간: Day 0 immediately after first pass
|
Defined as a eTICI 3 after first pass device
|
Day 0 immediately after first pass
|
|
Complete reperfusion
기간: Day 0 immediately after three passes
|
Defined as eTICI 3 after three passes
|
Day 0 immediately after three passes
|
|
Final near to complete reperfusion
기간: Day 0 at the end of the intervention
|
Defined as eTICI 2c/3 final
|
Day 0 at the end of the intervention
|
|
Final complete reperfusion
기간: Day 0 at the end of the intervention
|
Defined as eTICI 3
|
Day 0 at the end of the intervention
|
|
Time to achieve eTICI 2c or better revascularization
기간: Day 0
|
Time to achieve eTICI 2c or better revascularization
|
Day 0
|
|
Time between groin puncture to clot contact
기간: Day 0
|
Time between groin puncture to clot contact
|
Day 0
|
|
Rate of functional independence
기간: At 90days
|
Defined as a modified Rankin scale (mRS) 0-2
|
At 90days
|
|
Rate of excellent functional outcome
기간: At 90days
|
Defined as a mRS 0-1
|
At 90days
|
|
The distribution of mRs scores
기간: At 90days
|
Combining scores of 9 and 10
|
At 90days
|
|
Change in NIHSS from baseline to 24 hours
기간: Baseline and 24hours
|
Change in NIHSS
|
Baseline and 24hours
|
|
Rate of symptomatic and asymptomatic intracerebral hemorrhage
기간: At 24hrs
|
Assessment of symptomatic and asymptomatic intracerebral hemorrhage at MRI or CT scan 24h after thrombectomy
|
At 24hrs
|
|
Rate of parenchymal hematoma type 1 and 2
기간: At 24hrs
|
Assessment of parenchymal hematoma type 1 and 2
|
At 24hrs
|
|
Rate of all-cause mortality at 90 days
기간: At 90days
|
Assessment of all-cause mortality at 90 days
|
At 90days
|
|
Rate of periprocedural complications
기간: At 90days
|
Occurrence of emboli to new territory, vasospasm, dissection, perforation and subarachnoid hemorrhage
|
At 90days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Romain Bourcier, Nantes university hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- RC19_0174
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .